Drug Database
Back to search

Netherlands· NL-f474f3a0042d

Deltyba 25 mg, dispergeerbare tabletten

A delamanid product containing delamanid, registered in Netherlands by Otsuka Novel Products GmbH. The same ATC class is registered in 12 of our 19 countries.

ATC J04AK06

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedDeltyba 25 mg, dispergeerbare tablett…ATCJ04AK06REGISTER NO.NL-f474f3a0042dPACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about delamanidAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Delamanid is registered in 12 of 19 countries.

Countries holding a registration under ATC J04AK06 (delamanid), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 7 of them publish a price we can compare per daily dose
Search delamanid products by name

Delamanid · ATC J04AK06

12 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
DELAMANID
Manufacturer
Otsuka Novel Products GmbH
Country
Netherlands (NL)
ATC code
J04AK06
ATC class
Delamanid
Defined daily dose
0.2 g, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/13/875

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Delamanid in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All delamanid products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Deltyba
  • Liechtenstein · Deltyba
  • Norway · Deltyba

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b591d59c-9f9d-4248-b2b4-be7258b654d1
GET /v1/drugs/b591d59c-9f9d-4248-b2b4-be7258b654d1?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Dispergeerbare tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/deltyba-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Delamanid",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp127126",
  "excipients": [
    "CALCIUMSTEARAAT (E 470A)",
    "CROSPOVIDON (E 1202)",
    "HYPROMELLOSEFTALAAT",
    "KERSENSMAAKSTOF",
    "MANNITOL (D-) (E 421)",
    "NATRIUMZETMEELOCTENYLSUCCINAAT (E 1450)",
    "POVIDON K 25 (E 1201)",
    "SILICIUMDIOXIDE, GEHYDRATEERD (E 551)",
    "SUCRALOSE (E 955)",
    "TOCOFEROL, DL-ALFA (E 307)"
  ],
  "substances": [
    "DELAMANID"
  ],
  "leaflet_url": null,
  "authorised_at": "2014/04/28",
  "procedure_number": "EMEA/H/C/002552",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/13/875",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about delamanid.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console